MedPath

Differences in Postoperative Symptoms With Four Ureteral Stents

Not Applicable
Recruiting
Conditions
Urinary Stone
Interventions
Device: 4.8Fr Percuflex ureteral stents
Device: 6Fr Tria ureteral stents
Device: 6Fr Percuflex ureteral stents
Device: 4.8Fr Tria ureteral stents
Registration Number
NCT06083051
Lead Sponsor
University of Wisconsin, Madison
Brief Summary

This is a prospective randomized controlled trial designed to assess the differences in postoperative symptoms related to placement of a 6Fr Percuflex ureteral stents, 6Fr Tria ureteral stents, 4.8Fr Percuflex ureteral stents, and 4.8Fr Tria ureteral stents after ureteroscopy with laser lithotripsy for treatment of upper tract urinary stones. 272 participants will be enrolled and will be on study for up to approximately 10 weeks.

Detailed Description

The investigators will compare Ureteral Stent Symptom Questionnaire (USSQ) scores with each ureteral stent. Laser lithotripsy is a surgical procedure performed during stone surgeries. The Percuflex ureteral stent and Tria ureteral stent are FDA approved and clinically used in the United States.

A total of 3 clinic visits (i.e., pre-operative visit, the stent removal 1-2 weeks after surgery, and one post-operative visit 3-6 weeks after surgery) in addition to the surgery will be needed for this study. The patient's demographic information and medical background data will be collected from the medical record.

The USSQ will be administered twice:

1. At the time of stent removal (1-2 weeks after surgery ) (This is standard of care)

2. At the first postoperative follow-up after stent removal (3-6 weeks) (This is the standard of care).

The following information will be collected as secondary outcomes:

1. WisQOL which will be administered three times. It is UW standard of care for stone patients to complete the WisQOL at every clinic visit.

2. ER visits documented in patients chart

3. Unscheduled clinic follow-up documented in patient chart

4. Additional prescriptions for stent related symptoms documented by patient chart

5. Stent complications by fluoroscopy or image

6. Physician evaluation of the stent. Physicians will complete a one page survey at the end of the case evaluating the stent.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
272
Inclusion Criteria
  • Patients with renal or ureteral urinary stones who require endoscopic treatment and stent placement in the outpatient operating room.
Exclusion Criteria
  • Pregnant patients
  • Patients with transplant kidneys
  • Patients with irreversible coagulopathy
  • Patients with known ureteral stricture disease
  • Non-English speaking, vulnerable patients such as lacking of decision-making capability, prisoner, adult unable to consent, will not be enrolled.
  • Patients with planned staged procedures.
  • Patients who have stent placed before surgery.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
4.8Fr Percuflex ureteral stents4.8Fr Percuflex ureteral stents-
6Fr Tria ureteral stents6Fr Tria ureteral stents-
6Fr Percuflex ureteral stents6Fr Percuflex ureteral stents-
4.8Fr Tria ureteral stents4.8Fr Tria ureteral stents-
Primary Outcome Measures
NameTimeMethod
Ureteral Stent Symptom Questionnaire (USSQ) scores-Work Performanceat time of stent removal 3-6 weeks after surgery (up to 10 weeks on study)

USSQ is a 38-item questionnaire to evaluate symptoms and impact on quality of life of ureteral stents. The high scores indicate worse outcomes. It has 5 sections, urinary symptoms, pain, general health, work performance, and sexual matters. The Work Performance subscale score range from 3-15.

Ureteral Stent Symptom Questionnaire (USSQ) scores-Pain indexat time of stent removal 3-6 weeks after surgery (up to 10 weeks on study)

USSQ is a 38-item questionnaire to evaluate symptoms and impact on quality of life of ureteral stents. The high scores indicate worse outcomes. It has 5 sections, urinary symptoms, pain, general health, work performance, and sexual matters. The Pain subscale score range from 6-37.

Ureteral Stent Symptom Questionnaire (USSQ) scores-Pain Indexat time of stent removal 1-2 weeks after surgery (up to 4 weeks on study)

USSQ is a 38-item questionnaire to evaluate symptoms and impact on quality of life of ureteral stents. The high scores indicate worse outcomes. It has 5 sections, urinary symptoms, pain, general health, work performance, and sexual matters. The Pain subscale score range from 6-37.

Ureteral Stent Symptom Questionnaire (USSQ) scores-Urinary symptomsat time of stent removal 3-6 weeks after surgery (up to 10 weeks on study)

USSQ is a 38-item questionnaire to evaluate symptoms and impact on quality of life of ureteral stents. The high scores indicate worse outcomes. It has 5 sections, urinary symptoms, pain, general health, work performance, and sexual matters. The urinary subscale score range from 11-54.

Ureteral Stent Symptom Questionnaire (USSQ) scores-Sexual Mattersat time of stent removal 3-6 weeks after surgery (up to 10 weeks on study)

USSQ is a 38-item questionnaire to evaluate symptoms and impact on quality of life of ureteral stents. The high scores indicate worse outcomes. It has 5 sections, urinary symptoms, pain, general health, work performance, and sexual matters. The Sexual Matters subscale score range from 2-10.

Ureteral Stent Symptom Questionnaire (USSQ) scores-General Healthat time of stent removal 3-6 weeks after surgery (up to 10 weeks on study)

USSQ is a 38-item questionnaire to evaluate symptoms and impact on quality of life of ureteral stents. The high scores indicate worse outcomes. It has 5 sections, urinary symptoms, pain, general health, work performance, and sexual matters. The Pain subscale score range from 6-28.

Ureteral Stent Symptom Questionnaire (USSQ) scores-Sexual mattersat time of stent removal 1-2 weeks after surgery (up to 4 weeks on study)

USSQ is a 38-item questionnaire to evaluate symptoms and impact on quality of life of ureteral stents. The high scores indicate worse outcomes. It has 5 sections, urinary symptoms, pain, general health, work performance, and sexual matters. The Sexual Matters subscale score range from 2-10.

Secondary Outcome Measures
NameTimeMethod
Change in Quality of Life measured by WISQOL Scorespre-operative visit (baseline), the stent removal 1-2 weeks after surgery (up to 4 weeks on study), and one post-operative visit 3-6 weeks after surgery (up to 10 weeks on study)

WISQOL short form is a 6 item questionnaire which can be scored from 1 (worst outcome) to 5 (best outcome). The raw score range is 5-30. In the study, standardized total score is used. The range of the standardized total score is 0-100.

Number of Unscheduled Clinic Follow-Upsup to 10 weeks

Data collected from medical record.

Summary of Additional Prescriptions for Stent-Related Symptomsup to 10 weeks

Data collected from medical record.

Summary of Stent Complicationsup to 10 weeks
Physician Evaluation of Stent: Survey Scoresup to 10 weeks

Physicians will complete a one page survey at the end of the case evaluating the stent. Scores are from 0-5 where higher scores indicate a more positive evaluation.

Number of Emergency Room Visitsup to 10 weeks

Data collected from medical record.

Trial Locations

Locations (1)

University of Wisconsin School of Medicine and Public Health

🇺🇸

Madison, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath